Leap Therapeutics Files 8-K Report

Ticker: CYPH · Form: 8-K · Filed: Jan 28, 2025 · CIK: 1509745

Leap Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyLeap Therapeutics, INC. (CYPH)
Form Type8-K
Filed DateJan 28, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k, financials

TL;DR

LEAP filed an 8-K, likely routine financial updates.

AI Summary

On January 28, 2025, Leap Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events detailed in the provided text. The company, incorporated in Delaware, is located in Cambridge, MA.

Why It Matters

This 8-K filing indicates Leap Therapeutics is providing updates or submitting required financial documentation to the SEC, which is standard for public companies.

Risk Assessment

Risk Level: low — The filing appears to be a standard procedural update without immediate material news impacting the company's operations or stock.

Key Numbers

Key Players & Entities

FAQ

What specific 'Other Events' are being reported by Leap Therapeutics, Inc. in this 8-K filing?

The provided text of the 8-K filing does not specify the details of the 'Other Events' beyond listing it as an item information.

What is the significance of filing 'Financial Statements and Exhibits' on this 8-K?

Filing 'Financial Statements and Exhibits' indicates the company is submitting required financial information or supplementary documents to the SEC as part of its reporting obligations.

When was Leap Therapeutics, Inc. incorporated, and in which state?

Leap Therapeutics, Inc. was incorporated in Delaware, as stated in the filing.

What is the primary business address of Leap Therapeutics, Inc.?

The primary business address of Leap Therapeutics, Inc. is 47 Thorndike Street, Suite B1-1, Cambridge, MA 02141.

What is the Commission File Number for Leap Therapeutics, Inc.?

The Commission File Number for Leap Therapeutics, Inc. is 001-37990.

Filing Stats: 549 words · 2 min read · ~2 pages · Grade level 9.8 · Accepted 2025-01-28 08:00:32

Key Financial Figures

Filing Documents

01. Other

Item 8.01. Other Events On January 28, 2025, Leap Therapeutics, Inc. (the "Company") issued a press release entitled "Leap Therapeutics Reports Initial Clinical Data from Part B of DeFianCe Study and Part C of the DisTinGuish Study." The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference; provided, however that information on or connected to our website referenced in the Company's press release is expressly not incorporated by reference into or intended to be filed as a part of this Current Report on Form 8-K. Also on January 28, 2025, the Company posted an updated corporate presentation on its website, www.leaptx.com. A copy of the presentation is filed as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference. The information contained on, or that can be accessed from, the Company's website is not incorporated into, and does not constitute a part of, this Current Report on Form 8-K.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d)Exhibits. Exhibit Number Description 99.1 Press Release dated January 28, 2025 99.2 Leap Corporate Presentation 104 Cover Page Interactive Data File. (Embedded within the Inline XBRL document.)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LEAP THERAPEUTICS, INC. Dated: January 28, 2025 By: /s/ Douglas E. Onsi Name: Douglas E. Onsi Title: Chief Executive Officer and President

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing